Literature DB >> 28054314

Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis.

Till Plönes1,2, Mitja Fischer3, Kerstin Höhne3, Hiromi Sato4, Joachim Müller-Quernheim3, Gernot Zissel3.   

Abstract

Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that arises from the surface of the pleura and is associated with a history of asbestos exposure. The tumor is characterized by a strong local invasiveness and a poor response to any single modality therapy. Therefore clinical outcome of patients with MPM is poor and median survival time of untreated patients with MPM is 7 months from initial diagnosis. The Wilms Tumor Protein 1 (WT1) is a transcription factor which is highly expressed by MPM and is involved in cellular development and survival. We evaluated the role of WT1 in two human MPM cell lines (MSTO and H2052) expressing high levels of WT1. We performed a knockdown of WT1 using siRNA. Knockdown of WT1 was confirmed by Westernblotting. After knockdown of WT1 we investigated the effect on proliferation, chemoresistance, chemotaxis and migration. We could demonstrate that knockdown of WT1 suppresses chemoresistance in both cell lines compared with control (scrambled siRNA). Additionally, WT1 knockdown reduces proliferation, chemotaxis and invasiveness of mesothelioma cell lines. WT1 reduces malignancy of malignant mesothelioma cell lines and might be a new molecular target in mesothelioma therapy. Further investigations are needed to discover the mechanisms of chemoresistance depending on WT1.

Entities:  

Keywords:  Asbestos; Cancer; Chemoresistance; Cisplatin; Decortication; Drug; EMT; EPP; Epigenetics; Epithelial to mesenchymal transition; Met; P/D; Pleural; Pleuropneumonectomy; Stem cells; Wilms tumor

Mesh:

Substances:

Year:  2017        PMID: 28054314     DOI: 10.1007/s12253-016-0181-3

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  32 in total

1.  Inhibition of breast cancer cell growth by the Wilms' tumor suppressor WT1 is associated with a destabilization of beta-catenin.

Authors:  Teng-Fei Zhang; Shui-Qing Yu; Li-Shuang Guan; Zhao-Yi Wang
Journal:  Anticancer Res       Date:  2003 Sep-Oct       Impact factor: 2.480

Review 2.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

Authors:  Héctor Peinado; David Olmeda; Amparo Cano
Journal:  Nat Rev Cancer       Date:  2007-05-17       Impact factor: 60.716

3.  Frequent association of beta-catenin and WT1 mutations in Wilms tumors.

Authors:  S Maiti; R Alam; C I Amos; V Huff
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

4.  Survival after conservative (palliative) management of pleural malignant mesothelioma.

Authors:  N Merritt; C J Blewett; J D Miller; W F Bennett; J E Young; J D Urschel
Journal:  J Surg Oncol       Date:  2001-11       Impact factor: 3.454

5.  Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression.

Authors:  Mike Y Chen; Aaron J Clark; Dana C Chan; Joy L Ware; Shawn E Holt; Archana Chidambaram; Helen L Fillmore; William C Broaddus
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

6.  Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.

Authors:  Kei Kushitani; Yukio Takeshima; Vishwa Jeet Amatya; Osamu Furonaka; Akio Sakatani; Kouki Inai
Journal:  Pathol Int       Date:  2007-04       Impact factor: 2.534

7.  RNAi silencing of the WT1 gene inhibits cell proliferation and induces apoptosis in the B16F10 murine melanoma cell line.

Authors:  Diana E Zamora-Avila; Moisés A Franco-Molina; Laura M Trejo-Avila; Cristina Rodríguez-Padilla; Diana Reséndez-Pérez; Pablo Zapata-Benavides
Journal:  Melanoma Res       Date:  2007-12       Impact factor: 3.599

8.  Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers.

Authors:  Yusuke Oji; Shinichiro Miyoshi; Hajime Maeda; Seiji Hayashi; Hiroya Tamaki; Shin-Ichi Nakatsuka; Masayuki Yao; Eigo Takahashi; Yoko Nakano; Hirohisa Hirabayashi; Yasushi Shintani; Yoshihiro Oka; Akihiro Tsuboi; Naoki Hosen; Momotaro Asada; Tatsuya Fujioka; Masaki Murakami; Keisuke Kanato; Mari Motomura; Eui Ho Kim; Manabu Kawakami; Kazuhiro Ikegame; Hiroyasu Ogawa; Katsuyuki Aozasa; Ichiro Kawase; Haruo Sugiyama
Journal:  Int J Cancer       Date:  2002-07-20       Impact factor: 7.396

Review 9.  The many facets of the Wilms' tumour gene, WT1.

Authors:  Peter Hohenstein; Nicholas D Hastie
Journal:  Hum Mol Genet       Date:  2006-10-15       Impact factor: 6.150

10.  Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation.

Authors:  Jamie A Davies; Michael Ladomery; Peter Hohenstein; Lydia Michael; Anna Shafe; Lee Spraggon; Nick Hastie
Journal:  Hum Mol Genet       Date:  2003-11-25       Impact factor: 6.150

View more
  4 in total

1.  MiR-200a inhibits cell proliferation and EMT by down-regulating the ASPH expression levels and affecting ERK and PI3K/Akt pathways in human hepatoma cells.

Authors:  Wei-Feng Yao; Jun-Wei Liu; Dong-Sheng Huang
Journal:  Am J Transl Res       Date:  2018-04-15       Impact factor: 4.060

Review 2.  WT1: The Hinge Between Anemia Correction and Cancer Development in Chronic Kidney Disease.

Authors:  Wen-Chin Lee; Chien-Hua Chiu; Tian-Huei Chu; Yu-Shu Chien
Journal:  Front Cell Dev Biol       Date:  2022-04-06

3.  Cancer Stem Cells are Regulated by STAT3 Signalling in Wilms Tumour.

Authors:  Yanmei Liu; Xuexiang Gao; Shuo Wang; Xuemin Yuan; Yunqing Pang; Jian Chen; Jing Wang
Journal:  J Cancer       Date:  2018-04-06       Impact factor: 4.207

4.  Functional molecules in mesothelial-to-mesenchymal transition revealed by transcriptome analyses.

Authors:  Sara Namvar; Adrian S Woolf; Leo Ah Zeef; Thomas Wilm; Bettina Wilm; Sarah E Herrick
Journal:  J Pathol       Date:  2018-07-04       Impact factor: 7.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.